HER2 Support Group Forums - View Single Post - for those wondering what the recurrence risk is of T1a or1bNOMO breast cancer is

Lani · 11-03-2007, 09:26 PM

breast cancer patients-

There are limitations to our study. Most importantly, information on ADST use is not available in the SEER database. The proportion of patients who received adjuvant chemotherapy or hormonal therapy is unknown, and the BCSS calculated from SEER data may somewhat overestimate the outcome that would be found in an entirely untreated population. Data on tumor recurrence is not provided in the SEER database. However, evidence suggests that the accuracy of cause-of-death coding for cancer patients on death certificates and in SEER is high.43-46 Although the range of follow-up is long, the median is only 64 months. Nevertheless, because of the large number of patients available from SEER and the fact that 76% of patients are still at risk at 10 years, we can estimate 10-year survival with a high degree of confidence. Hormone receptor status was not measured in a central laboratory, and is not standardized in the population. Information on some other prognostic factors, such as lymphovascular invasion and human epidermal growth factor 2 (HER-2) status, is unavailable. Our nomograms allow for calculation of the probability of BCSS based on individual characteristics, but they do not consider the extent of comorbidities in the calculation of probability of non-BCSS. The Adjuvant! Online program can be used in conjunction with our nomograms to incorporate comorbidities into the estimation of individual non-BCSS probability.

Our data are derived from a large, population-based cohort and have a number of practical or clinical implications. T1a,bN0M0 cases overall have an excellent prognosis, but the nomograms will help clinicians identify who may be at higher risk of BCSM and assist in ADST decision making. Because most of these patients die as a result of other causes, many of which are at least partly lifestyle related (eg, cardiovascular), a healthy lifestyle and the management of non–breast cancer–related health problems in these patients are important.

11-03-2007, 09:26 PM	#4
Lani Senior Member Join Date: Mar 2006 Posts: 4,783	the concluding paragraph--it was based on SEER study which represents ~26% of all US breast cancer patients- There are limitations to our study. Most importantly, information on ADST use is not available in the SEER database. The proportion of patients who received adjuvant chemotherapy or hormonal therapy is unknown, and the BCSS calculated from SEER data may somewhat overestimate the outcome that would be found in an entirely untreated population. Data on tumor recurrence is not provided in the SEER database. However, evidence suggests that the accuracy of cause-of-death coding for cancer patients on death certificates and in SEER is high.43-46 Although the range of follow-up is long, the median is only 64 months. Nevertheless, because of the large number of patients available from SEER and the fact that 76% of patients are still at risk at 10 years, we can estimate 10-year survival with a high degree of confidence. Hormone receptor status was not measured in a central laboratory, and is not standardized in the population. Information on some other prognostic factors, such as lymphovascular invasion and human epidermal growth factor 2 (HER-2) status, is unavailable. Our nomograms allow for calculation of the probability of BCSS based on individual characteristics, but they do not consider the extent of comorbidities in the calculation of probability of non-BCSS. The Adjuvant! Online program can be used in conjunction with our nomograms to incorporate comorbidities into the estimation of individual non-BCSS probability. Our data are derived from a large, population-based cohort and have a number of practical or clinical implications. T1a,bN0M0 cases overall have an excellent prognosis, but the nomograms will help clinicians identify who may be at higher risk of BCSM and assist in ADST decision making. Because most of these patients die as a result of other causes, many of which are at least partly lifestyle related (eg, cardiovascular), a healthy lifestyle and the management of non–breast cancer–related health problems in these patients are important.